ATE429447T1 - Aufreinigung von her-2-varianten - Google Patents

Aufreinigung von her-2-varianten

Info

Publication number
ATE429447T1
ATE429447T1 AT04738948T AT04738948T ATE429447T1 AT E429447 T1 ATE429447 T1 AT E429447T1 AT 04738948 T AT04738948 T AT 04738948T AT 04738948 T AT04738948 T AT 04738948T AT E429447 T1 ATE429447 T1 AT E429447T1
Authority
AT
Austria
Prior art keywords
purification
provides
chromatography
variant
variants
Prior art date
Application number
AT04738948T
Other languages
English (en)
Inventor
Marie Eskling
Klaus Gregorius Nielsen
Original Assignee
Bn Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bn Immunotherapeutics Inc filed Critical Bn Immunotherapeutics Inc
Application granted granted Critical
Publication of ATE429447T1 publication Critical patent/ATE429447T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
AT04738948T 2003-06-25 2004-06-24 Aufreinigung von her-2-varianten ATE429447T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48231503P 2003-06-25 2003-06-25
DKPA200300954 2003-06-25
PCT/DK2004/000451 WO2004113377A1 (en) 2003-06-25 2004-06-24 Purification of her-2 variants

Publications (1)

Publication Number Publication Date
ATE429447T1 true ATE429447T1 (de) 2009-05-15

Family

ID=33542436

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04738948T ATE429447T1 (de) 2003-06-25 2004-06-24 Aufreinigung von her-2-varianten

Country Status (12)

Country Link
EP (2) EP2090586A1 (de)
JP (1) JP4579912B2 (de)
AT (1) ATE429447T1 (de)
AU (1) AU2004249362B2 (de)
CA (1) CA2530233C (de)
DE (1) DE602004020769D1 (de)
DK (1) DK1641819T3 (de)
ES (1) ES2325584T3 (de)
MX (1) MXPA05013389A (de)
NO (1) NO20055948L (de)
NZ (1) NZ544017A (de)
WO (1) WO2004113377A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763452B2 (en) 2003-06-25 2010-07-27 Bn Immunotherapeutics, Inc. Purification of HER-2 variants
AU2006228872A1 (en) * 2005-03-31 2006-10-05 Pharmexa A/S Immunogenic EGFR peptides comprising foreign Tcell stimulating epitope
NZ575388A (en) * 2006-10-06 2012-03-30 Bn Immunotherapeutics Inc Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
EP4211468A4 (de) 2020-09-11 2024-10-09 Glympse Bio, Inc. Ex-vivo-proteaseaktivitätsdetektion für krankheitsnachweis/-diagnostik, einstufung, überwachung und behandlung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
KR100731820B1 (ko) 1998-10-05 2007-06-25 파멕사 에이/에스 치료적 백신화를 위한 새로운 방법
WO2000044899A1 (en) * 1999-01-29 2000-08-03 Corixa Corporation Her-2/neu fusion proteins
CA2481509A1 (en) * 2002-04-11 2003-10-23 Suzanna Tatarewicz Her-2 receptor tyrosine kinase molecules and uses thereof

Also Published As

Publication number Publication date
CA2530233A1 (en) 2004-12-29
NO20055948L (no) 2005-12-14
AU2004249362A1 (en) 2004-12-29
EP1641819A1 (de) 2006-04-05
AU2004249362B2 (en) 2011-08-25
JP2007523615A (ja) 2007-08-23
ES2325584T3 (es) 2009-09-09
DE602004020769D1 (de) 2009-06-04
NZ544017A (en) 2008-04-30
DK1641819T3 (da) 2009-08-03
MXPA05013389A (es) 2006-03-17
EP2090586A1 (de) 2009-08-19
EP1641819B1 (de) 2009-04-22
CA2530233C (en) 2012-09-11
JP4579912B2 (ja) 2010-11-10
WO2004113377A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
EP3805248A3 (de) Prozess, um antikörper und therapeutische produkte zu konzentrieren
WO2003062375A3 (en) Stabilizing polypeptides which have been exposed to urea
WO2002069232A3 (en) Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
CY1109715T1 (el) IL-1β ΔΕΣΜΕΥΤΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΚΑΙ ΘΡΑΥΣΜΑΤΑ ΑΥΤΩΝ
WO2006041934A3 (en) Methods and compositions for improving recombinant protein production
WO2008013454A3 (en) Immunogenic compounds and protein mimics
WO2005111066A3 (en) Polypeptides from non-typeable haemophilus influenzae
ATE551352T1 (de) Peptidakzeptorbindungsverfahren
ATE444308T1 (de) Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
MXPA03008715A (es) Reduccion de la inmunogenicidad de proteinas de fusion.
WO2000056901A3 (en) Linear and circular expression elements
EP1365025A4 (de) Agarase und gen dafür
WO2007130535A3 (en) Novel protein fusion/tag technology
WO2006053021A3 (en) Methods for engineering polypeptide variants via somatic hypermutation and polypeptides made thereby
DE602004020769D1 (de) Aufreinigung von her-2-varianten
EA200600102A1 (ru) Очистка вариантов her-2
WO2003016904A3 (en) Peptide sequence tags and method of using same
WO2002062964A3 (en) Ap1 amine oxidase variants
DK1592439T3 (da) Fremgangsmåde til fremstilling af en albuminoplösning
WO2002077648A3 (en) Pathogenic and commensal vaccine antigens
WO2002063009A8 (en) Lp mammalian proteins; related reagents
DE602005016857D1 (de) Verfahren zur Herstellung von Tripeptid-Zwischenprodukten zur Herstellung von LHRH-Antagonisten
ATE397753T1 (de) Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung
WO2005003289A8 (en) Ap1 amine oxidase variants
DE60217972D1 (de) Methode zur erhöhung der effizienz von enzymatischen aufreinigungsprozessen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1641819

Country of ref document: EP